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This paper summarizes the clinical phenomenology of multiple chemical sensitivity (MCS), outlines
the concepts and evidence for the olfactory-limbic, neural sensitization model for MCS, and
discusses experimental design implications of the model for exposure-related research. Neural
sensitization is the progressive amplification of responsivity by the passage of time between
repeated, intermittent exposures. Initiation of sensitization may require single toxic or multiple
subtoxic exposures, but subsequent elicitation of sensitized responses can involve low or nontoxic
levels. Thus, neural sensitization could account for the ability of low levels of environmental
chemicals to elicit clinically severe, adverse reactions in MCS. Different forms of sensitization
include limbic kindling of seizures (compare temporal lobe epilepsy and simple partial seizures) and
time-dependent sensitization of behavioral, neurochemical, immunological, and endocrinological
variables. Sensitized dysfunction of the limbic and mesolimbic systems could account in part for
many of the cognitive, affective, and somatic symptoms in MCS. Derealization (an alteration in
perception making familiar objects or people seem unfamiliar or unreal) is a common MCS
symptom and has been linked with limbic dysfunction in clinical neuroscience research.
Sensitization is distinct from, but interactive with, other neurobiological learning and memory
processes such as conditioning and habituation (compare adaptation or tolerance). In previous
studies, hypotheses for MCS involving sensitization, conditioning, and habituation (adaptation)
have often been considered in isolation from one another. To design more appropriate chemical
exposure studies, it may be important to integrate the various theoretical models and empirical
approaches to MCS with the larger scientific literature on individual differences in these potentially
interactive phenomena. Environ Health Perspect 105(Suppl 2):457-466 (1997)
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This paper outlines the possible relationships
between the olfactory-limbic system and
neural sensitization model for multiple
chemical sensitivity (MCS) (1) and certain
exposure-related symptoms; and discusses
potential interactions between individual
differences in neural sensitization, con-
ditioning (context), and habituation (tol-
erance; adaptation) that might affect
experimental design in MCS studies. We
describe the model briefly, using data and
conclusions from our laboratory studies on
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chemically sensitive human subjects to illus-
trate certain points. Research on chemically
intolerant subjects thus far indicates that
they a) exhibit bidirectional variability
around an unstable set point (2) or failure
ofhabituation over time; b) report certain
lifetime patterns ofmedical (3-5) and psy-
chiatric (6-9) conditions that require expla-
nation in any MCS model; c) present more
complex clinical phenomenology than
chemical avoidance behaviors alone (3,4).
Multiple Chemical Sensitivity
Clinical Observations That
Require Explanation
It is essential to note that the clinical
observations summarized below represent a
mixture of anecdotal and controlled data
from the published literature, with relevant
citations. Much of the specific epidemio-
logic and laboratory study evidence needed
to support particular points is not avail-
able. At the same time, these concepts rep-
resent a core of clinical information that
requires articulation in order to design
proper studies for testing the assumptions
and various mechanistic hypotheses for
MCS. MCS is a chronic, polysymptomatic
condition. Affected individuals report
recurrent flares of illness when exposed to
low levels ofenvironmental chemicals (e.g.,
pesticides, solvents), common foods (e.g.,
milk, chocolate, wheat, sugar), multiple
drugs, and other ingestants (e.g., alcohol,
chlorinated water) (10). Women represent
70 to 80% ofthe affected population (10).
The illness process involves two steps: initi-
ation and elicitation (10). Many (11), but
not all (12), MCS patients report an iden-
tifiable, acute, or subacute exposure event
in which they inhaled, absorbed, or
ingested toxic levels ofa particular chemi-
cal agent. Typically, the initiating sub-
stances are pesticides or solvents (4,5).
Patients report recovery from the more
classical, substance-specific toxic effects,
followed by a deterioration in overall
health over a period ofweeks to months.
Subsequent eliciting agents are numerous
and diverse in chemical structures, but
often similar in their adverse effects.
Triggers can include previously tolerated
levels ofpesticides, perfumes, deodorizers,
gasoline, paint, new carpet, fresh news-
print, or traffic exhaust, as well as foods,
drugs, and alcohol (4). Patients report the
ability to return to a relatively normal base-
line if they avoid exposures to inciting
agents (13). Some investigators postulate
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that adaptation to chronic exposures
dampens the degree of reactivity to expo-
sures under certain circumstances (5).
They suggest that this adaptation necessi-
tates removal from chronic exposures prior
to acute sensitivity testing to avoid type II
error (5,10).
Individual reactions to many chemically
unrelated substances include cognitive diffi-
culties with concentration and memory,
neuromuscular, gastrointestinal, affective,
musculoskeletal, respiratory, and cardiac
dysfunctions, and fatigue (3,4,11,14).
Miller and Mitzel (4) found that cognitive
symptoms of MCS such as slowed think-
ing, memory problems, and concentration
difficulty are among the most severe dys-
functions, whereas feelings of unreality/
spaciness and lightheadedness are among
the most frequent features ofthe condition
(15). Symptoms ofa given adverse reaction
can begin within minutes or be delayed for
up to 24 hr after a given exposure or inges-
tion (16). Once triggered, reactions last
from minutes to several days, even if the
exposure is terminated promptly (16).
Different phases of the same reaction can
involve activated states such as insomnia,
anxiety, or irritability, and deactivated states
such as sleepiness or depression in the same
person, i.e., bidirectionality (5,10,16).
MCS patients also report increased lifetime
rates ofphysician-diagnosed rhinitis, sinusi-
tis, menstrual disorders, irritable bowel,
arthritis, migraine headaches, breast or
ovarian cysts, depression, and panic disor-
der (3,6-8). MCS patients usually show
marked avoidant behaviors toward inhaled
chemicals (for which onset ofadverse reac-
tions is within minutes), but often extreme
cravings for foods such as sweets (for which
onset of adverse reactions is delayed by
hours) (5). MCS reactions include somatic
manifestations as well, involving autonomic
dysfunction or inflammation at multiple
sites (17-19).
A recent study indicated that MCS
patients make an average of 23 health care
provider visits per year (20). This poorly
understood condition is costly in terms
ofworker's compensation, personal injury
litigation, and health care utilization.
Although definitive population-based
studies have not been published, the esti-
mated prevalence of MCS ranges from 0.2
to 4% of the general population (21,22).
Morrow et al. (23,24) found that 60% of
solvent-exposed industrial workers mani-
fested symptoms of illness from chemical
odor. Bell et al. (21,25-27) demonstrated
less severe self-reported chemical odor
intolerance in 15 to 30% ofyoung adult
college student (mean ages 18-19 years)
and active retired community elderly
(mean ages 68-76 years) samples. In con-
trast with MCS populations (3,4,6), nei-
ther the college students nor the elderly
individuals with chemical odor intolerance
worked in the chemical or associated
industries or perceived themselves as dis-
abled by chemical-related illness at the
time ofthe study.
MCS is a complex condition that, once
established, defies traditional dose-response
relationships of toxicology. That is, in
MCS, low doses trigger large responses.
The symptom of illness from low-level
chemical odors is common in populations
not motivated by secondary gain in terms
of worker's compensation or disability
claims (22). The manifestations ofadverse
reactions are multiple and individualized,
and often include involvement of the
central nervous system (CNS) (3,4).
Olfactory-Limbic and Neural
Sensitization Model
The olfactory-limbic and neural sensi-
tization model proposes that individual dif-
ferences in reactivity to environmental
substances in MCS derive from neurobio-
logically based sensitization ofthe olfactory,
limbic, mesolimbic, and related pathways of
the CNS (1,28). The nose is a direct path-
way into the limbic system both for neural
signals (odor-olfactory and irritant-trigem-
inal) (29,30) and for transport of many
molecules (31,32). Among the sensory sys-
tems, only the olfactory system lacks a
blood-brain barrier (29,30). The olfactory
bulb, amygdala, and hippocampus are
interconnected parts ofa phylogenetically
older portion of the brain that is particu-
larly vulnerable to sensitization processes
(33,34). Repeated intermittent exposures
to a given stimulus lead to progressively
increased levels ofresponsivity over time in
those structures (1,33,34). Sensitization
then persists without reexposures for long
periods of time. As a result, Stewart and
Badiani (35) refer to sensitization as a basic
form of learning and memory. Indeed,
drugs that can interfere with the neurobiol-
ogy oflearning, such as excitatory amino
acid antagonists or protein synthesis
inhibitors, can also block acquisition ofsen-
sitization (36-38). The limbic region par-
ticipates in regulation of a broad range of
psychological and physiological functions,
including anger, fear, learning and mem-
ory, reproduction, eating, drinking, auto-
nomic activity, and pain (39-41). Limbic
dysfunction could lead to polysymptomatic
conditions involving neurobehavioral and
somatic manifestations (1).
Kindling
Kindling is the prototypical sensitization
process, in which a low-level electrical or
chemical stimulus that initially had little or
no effect on behavior eventually elicits per-
sistent vulnerability to electrographic and
behavioral seizures after daily repetition for
10 to 14 days (42). Kindling is considered
an animal model for temporal lobe epilepsy
(TLE) in humans. Full kindling is unlikely
to provide an explanation for most MCS
cases, as increased rates ofTLE per se and
other clinically obvious seizure disorders are
not present in the majority ofMCS patients.
However, partial kindling to a point short
of seizures produces persistent changes in
electrical firing patterns and in aggressive
and social behaviors ofanimals (43). Many
environmental chemicals, especially pesti-
cides (44-46) and the solvent toluene
(34), induce chemical kindling or partial
kindling, or facilitate electrical kindling of
the amygdala in animals. Rossi (42) has
recently published a detailed examination
ofthe basic neurobiology issues in kindling
as a model for MCS.
No studies have yet directly examined
MCS patients for electrophysiological evi-
dence ofpartial kindling, TLE (complex
partial seizures), simple partial seizures, or
subclinical seizure disorders. In view ofthe
association ofhigh rates ofpolycystic ovary
disease in women with TLE (47), a history
of ovarian cysts (3) could suggest focal
amygdala or hypothalamic dysfunction
resulting in reproductive hormone dysreg-
ulation in MCS patients. Moreover, Bell et
al. have shown that young adults (48) and
middle-aged women (49,50) with chemical
odor intolerance have higher scores than
do their chemically tolerant peers on the
McLean Limbic Symptom Checklist. This
scale is based on self-ratings of the fre-
quency of ictal symptoms ofTLE such as
somatic, sensory, behavioral, and memory
dysfunctions (51).
Several different studies have shown that
MCS patients have an inordinatelyhigh rate
ofpast or comorbid depression and panic
disorder (6-8), conditions also associated
with limbic system dysfunction. Notably, a
subset ofpanic disorder patients with symp-
toms ofderealization and other sensory dis-
tortions actually exhibit electrophysiological
patterns ofsimple partial seizures (e.g., uni-
lateral delta-theta slowing over temporal
regions) during attacks in supermarkets and
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malls monitored with ambulatory electro-
encephalogram (EEG) (52). In addition,
nasal inhalation of an olfactory stimulus
odor (sweet orange in propylene glycol) to
stimulate the temporolimbic regions in
such panic disorder patients who were not
experiencing an attack elicited increases in
EEG delta (slow wave, 2-4 Hz) activity not
seen in panic patients without the derealiza-
tion symptom or in normals (53). In other
words, panic patients with temporolimbic
symptoms ofderealization and other sen-
sory distortions show epileptiform EEG
alterations with ambulatory monitoring
and/or odor inhalation. By analogy, odor-
elicited temporal lobe dysfunction could
explain in part the derealization symptom
in MCS patients. However, such odor reac-
tivity may be present only under conditions
ofsensitization, not necessarily in a single,
isolated test (28).
Time-dependent
Sensitization
Animal studies have permitted systematic
examination of the phenomenology and
mechanisms oftime-dependent sensitiza-
tion (TDS). Among various efferents, the
amygdala sends excitatory input to the
nucleus accumbens of the dopaminergic
mesolimbic pathway (54). As a result, the
amygdala can modulate (but is not neces-
sarily required for) another nonkindling
type ofneural sensitization known as time-
dependent sensitization (55). TDS is the
progressive increase in responsivity of a
given outcome measure with the passage of
time between the initial and later exposures
to a pharmacological or nonpharmacologi-
cal stimulus or stressor (56). Agents that
differ widely in their structural and phar-
macological properties can all induce,
elicit, and/or modulate TDS (56-60),
including stimulants, p opioids, glucocor-
ticoids, tranquilizers, antidepressants,
immunosuppressants, pertussis or cholera
toxins, and neuromodulators such as sub-
stance P, and volatile organic agents such
as ethanol (61), toluene (62), or formalde-
hyde (63). Sensitizable outcomes may be
behavioral, neurochemical, immune, or
endocrine. Outcomes may also be bidirec-
tional (increases or decreases), depending
on the individual's past history with the
sensitizing or cross-sensitizing agent
(61,64). Convulsions are not necessarily
involved in TDS, and drugs such as
anticonvulsants that block kindling do not
prevent TDS-type effects (65).
Previous research suggests that the
patterns of response to exposures under
different time factors can distinguish sensi-
tization from other neurobehavioral
processes such as classical conditioning or
habituation (Table 1). For example, the
initial response to a given stimulus may be
of magnitude 1+ in sensitization and
habituation. The magnitude of the initial
response to a conditioned stimulus (CS)
would be 0 in conditioning. Namely, only
the unconditioned stimulus (UCS) can
elicit the 1+ biological response, and the
UCS would not be retested; the initial
response to the unconditioned stimulus
that is paired with the UCS is 0. Thus, the
response magnitude upon initiation could
distinguish conditioning from sensitiza-
tion and habituation. However, if the
stimulus is given again soon after the ini-
tial exposure, the response is dampened to
0 in habituation, while it remains 1+ in
sensitization and grows from 0 to 1+ to
the CS in conditioning. Thus, rapid repe-
tition of a stimulus could distinguish
habituation from the other two phenom-
ena. After the passage of time, the
magnitude of the response in sensitization
(amplification ofresponsivity by passage of
time) would be 3+, whereas it would be 1+
in habituation (restoration of responsivity
by passage of time without reexposures).
In contrast, the magnitude ofthe response
to the CS in conditioning would diminish
because ofa lack ofrepeated pairings with
the UCS or even oppose that ofthe UCS
(66). Thus, delay between reexposures to a
stimulus could distinguish sensitization
from the other two phenomena.
Sensitization is further complicated by
the potential for interaction with condi-
tioning processes in a context-dependent
manner (Table 2). That is, ifthe initiating
and eliciting stimuli are given in the same
physical environment, then it is possible to
elicit the sensitized response only in that
same, familiar environment (35,67).
Testing for elicitation ofsensitization in an
environment different from the one where
the process was initiated, (e.g., testing in a
laboratory when the illness is reported at
work) will elicit only a baseline magnitude
ofresponse. In this circumstance, the sensi-
tization may still be present, but not
observable. By analogy, the degree of nov-
elty of environments, in ascending order
would be home, work, MCS laboratory
(Table 2). In context-dependent sensitiza-
tion, it is preferable to both initiate and
elicit sensitization in the laboratory; other-
wise, testing in a novel site after initiation
in a familiar setting (4) could fail to elicit
sensitization when it is actually present.
These context-related concepts derive
from previous animal research. Badiani et
al. (67) studied the interaction of stimu-
lant drugs with the environment (home
versus novel cage for both initiating and
test exposures) and with individual differ-
ences in behavior over a 1-week protocol.
They found that it was possible to induce a
greater degree ofsensitization of rotational
behavior if both initiating and test expo-
sures were given in a novel cage, rather
than if the exposures were all given in the
home cage. This design parallels previous
Table 1. Predicted size of response compared with unexposed controls to a repeated stimulus in sensitization,
conditioning, and habituation, based on time since the individual's previous exposure.
(a) Reactivity to initial (b) Effect oftime (c) Effect of more time,
exposure in environment with rapid reexposure without rapid reexposure
Sensitizationa + + +++
Conditioning 0 (CR) +(CR) 0 (CR)
Habituationa + 0 +
CR, conditioned response to a previously neutral, biologically inactive stimulus (conditioned stimulus [CS]) initially
paired with a biologically active stimulus (unconditioned stimulus [UCS], which initially causes a positive uncondi-
tioned response [UCRI). NOTE: All three processes can occur in the same individual for a given exposure. The net
observed effect will be a complex summation of their respective underlying effects. Within this table, assume the
responses represent outcomes for each process by itself. Sensitization proceeds by the passage of time after the
initial exposure without further reexposures. Retests produce progressively larger responses. Conditioning pro-
ceeds by repeated pairing of UCS and CS starting with the initial exposure until CS alone elicits CR. Repeated
retests of CS without repairing with UCS overtime extinguishes CR and produces progressively smaller responses.
Habituation proceeds by continuous exposure or frequent repetition of exposures. Retests produce progressively
smaller responses. "If repeated chemical exposures were to induce both sensitization and habituation together in
varying degrees, then the net observed response might be modified from the simple examples in the table above.
That is, under time pattern b, the net response would be present but dampened [i.e., 0 to 1/2 +, masked or
adapted by concomitant habituation (5,10)]. Under time pattern c, the net response would be present and ampli-
fied as in the sensitized state [i.e., +++, unmasked or de-adapted by the removal of habituation (5,10)]. If repeated
chemical exposures were to induce both sensitization and conditioning together, then the net observed response
might be one ofthe scenarios shown in Table 2.
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Table 2. Predicted size of context-dependent response to a given chemical during challenge testing by interaction
with environmental factors, from the sensitization model for MCS without dishabituation or de-adaptation (35,67).
Assume a baseline level of chronic symptoms at 1+.
Response vs baseline
Live in Sensitize to chemical Test chemical Predicted size after Predicted size after
environment in environment in environment testchemical placebo
[i] Home Home Home 2+ 1+
[ii] Home Work Work 3+ 1-2+
[iii] Home MCS laboratory MCS laboratory 4+ 2+
[iv] Home Home MCS laboratory 1-2+ 1-2+
[v] Home Work MCS laboratory 1-2+ 1-2+
The degree of novelty of a given environment (scenarios iiand iiishould heighten sensitization if the initiation and
elicitation both occurthere. A novel environment should dampen the size of an elicited response if the initiation is
removed from the environment in which testing for elicitation occurs (scenarios ivand v). Research scenario iii is
more likely than iv or v to distinguish active from placebo. However, fluctuations in baseline symptomatology
without dishabituation make it difficult to differentiate active from placebo in all scenarios, especially ivand v.
human studies in which investigators gave
the sensitizing exposures (session a) and
test exposures (session b) in the same novel
laboratory setting (49,50,68). Badiani et
al. (67) also demonstrated that the ani-
mals with lower responses to amphetamine
during the first session exhibited the
greater sensitization ofrotational behavior
after 7 days when sensitizing and test doses
were given in a novel environment. In
contrast, animals with higher responses to
amphetamine during session a exhibited
habituation, not sensitization, ofrotational
behavior after 7 days when all sensitizing
and test doses were given in the home
environment. Similarly, Sorg et al. (63)
noted differential sensitization to formal-
dehyde as a function of initial locomotor
responsivity to a novel environment.
Sensitization is not merely a type of
conditioning. Animal studies have demon-
strated the ability to extinguish the condi-
tioned responsivity to the experimental
context by giving sham exposures (e.g.,
saline injections) without eliminating the
sensitized response to the actual substance
(e.g., a drug) in the same setting (69). Re-
exposure to the original stimulus immedi-
ately elicits the sensitized response despite
extinction ofthe context responsivity. It is
also possible to initiate and elicit sensitiza-
tion in acontext-independent manner (70).
For this type ofsensitization, the environ-
ment in which the initiating stimulus is
given varies among exposures; whenever
the stimulus is readminstered, the later
responses will be amplified, i.e., sensitized,
regardless of the environment in which
the reexposures occur. One animal study
suggests that animals with the greatest
behavioral reactivity to novelty are more
prone to develop both stimulant drug self-
administration (71) and context-dependent
rather than context-independent sensitiza-
tion. These findings raise the possibility of
studying analogous individual differences
in human subjects to explain why one
person progresses into severe MCS and
another does not.
A sensitization model also accomodates
possible comorbid psychiatric disorders
and stress factors in MCS. TDS is a neuro-
biological process, but drugs and stress
(physical or psychological) can cross-sensi-
tize (initiate TDS) when tested later in
time (56,72,73). Hormones present in the
physiological stress response (compare with
glucocorticoids) may be required for initia-
tion ofTDS to stress (74), though not
necessarily to pharmacologic agents (75).
Estrogens favor acceleration ofthe develop-
ment ofTDS in animals (76), and females
sensitize more readily than do males (77).
TDS is emerging as a leading model for
various chronic recurrent disorders such as
drug craving and addiction (78), posttrau-
matic stress disorder (79), bipolar disorder
(80), recurrent unipolar depression (80),
and eating disorders such as bulimia (56).
Various investigators have linked MCS
with all ofthese disorders with the notable
exception ofdrug abuse (81). Antelman
(57) and Bell (28,81) have reviewed the
extensive overlaps between MCS and TDS.
Bell et al. have found increased histories of
drug problems in the families ofchemically
intolerantyoung adults (48) and ofalcohol
problems in the families of chemically
intolerant middle-aged adults (50). Thus,
the genetic vulnerability to substance abuse
problems may be present, but may not be
expressed as such in MCS patients.
Another leading MCS symptom is
concentration difficulty (4,15). This symp-
tom may have neurophysiological correlates
in the slow EEG frequency, absolute theta
(4-8 Hz). That is, normal young adults
trained to produce increased amounts of
EEG theta perform more poorly on tests of
vigilance than do controls trained to pro-
duce decreased amounts oftheta (82). We
have studied temporoparietal theta activity
among young adults with depressed affect
by using nasal inhalation offiltered room
air immediately following a series oflow-
level chemical exposures (n-butanol, galax-
olide, propylene glycol) and other tasks.
Under those conditions, we found increased
theta at rest after the chemicals within the
chemically intolerant subset compared with
those who reported tolerating chemicals
(83). Notably, children with attention-
deficit/hyperactivity disorder (ADHD) also
exhibit increased levels of EEG theta
activity, especially during cognitive tasks
(84,85), which researchers have linked
with feelings ofunreality (84). In a recent
survey, chemically intolerant young men
reported an increased rate of childhood
ADHD diagnoses (86). The dopaminergic
pathways involved in TDS have also been
implicated inADHD (87).
Bell et al. also have evidence for TDS
ofthe endogenous opioid, plasma P-endor-
phin (2), and ofcardiovascular measures
(88) over multiple laboratory sessions
involving foods and stress in older adults
with moderate levels of chemical odor
intolerance. The endorphin levels of the
chemically intolerant subjects were gener-
ally elevated, but changed direction from
session to session relative to those of the
normals. In addition, greater initial psycho-
logical distress correlated with lower endor-
phin levels later in the study for the
chemically intolerant as contrasted with
higher endorphin levels under the same
conditions for the normals (2). The chemi-
cally intolerant group also had waking dias-
tolic blood pressures that were higher on
the second than on the first days in the lab-
oratory, whereas the normals showed the
opposite pattern (88). Despite this variabil-
ity, averaged over six measurements, waking
blood pressures ofthe chemically intolerant
elderly were higher overall than those of
their normal peers. Bell et al. have found
increased diastolic blood pressures and/or
heart rate over time in two subsequent labo-
ratory studies ofchemically intolerant indi-
viduals in which chemical exposures were
given (49,50). Together, the data suggest
instability ofcertain physiological variables
between measurements and paradoxical
reversals in the direction of some stress-
related responses for chemically intolerant
individuals over time. The findings are
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consistent with Antelman et al.'s (61,64)
data on bidirectionality in TDS. Higher
peripheral endorphin levels could lead to
nonimmunological release of histamine
from mast cells (89). Ifso, endorphin could
account for some ofthe allergylike symp-
toms such as rhinitis, breathing problems,
or hives reported in MCS patients without
atopy (3,4,90). Moreover, p opioids such
as [-endorphin can initiate TDS in animal
studies (58) and can modulate cardiovas-
cular tone in human subjects (91).
The same group ofchemically intoler-
ant elderly described above also exhibited
objective polysomnographic sleep patterns
such as decreased total sleep time, increased
waking, and decreased rapid-eye movement
sleep, despite only slightly elevated subjec-
tive ratings ofsleep disturbance compared
with chemically tolerant controls (92).
Milk, a commonly implicated food incitant
in MCS (4), was associated with poorer
sleep than was soy beverage in the chemi-
cally intolerant group. One ofseveral possi-
ble neurochemical bases for the aroused
sleep pattern that would be consistent with
TDS is increased dopamine activity and/or
responsivity (DA) (93), e.g., in mesolimbic
pathways (94). Many but not all animal
studies ofTDS have reported progressive
increases in mesolimbic DA activity during
induction ofTDS (54,59). DA is also a
major neurotransmitter in the olfactory
bulb for odor discrimination (94) and in
the hypothalamus for inhibition of the
reproductive/stress hormone prolactin (95).
Plasma prolactin levels are accessible
indicators of CNS dopamine (95,96).
That is, increased hypothalamic dopamine
has been shown to act as prolactin inhi-
bitory factor, i.e., decreasing prolactin out-
put into the blood. Prolactin is often
elevated in cases ofpsychological or physi-
ological stress (97). Consequently, serum
prolactin could offer an objective correlate
of sensitization and of stress responses. As
part of a study ofsubsequent blood pres-
sure sensitization (49), Bell et al. examined
baseline 4 P.M. resting serum prolactin
levels (drawn upon study enrollment and
assayed with a standard commercial kit) in
middle-aged women with and without self-
rated chemical odor intolerance. Data from
the depressed and nondepressed controls
without chemical intolerance were aver-
aged in this analysis; the resulting two
groups (CI and non-CI) did not differ in
mean levels ofpsychological distress (SCL-
90-R Global Severity Index, p= 0.969).
Sitting and standing blood pressures were
then taken without concomitant chemical
exposures at the beginning and end oftwo
sessions, spaced one week apart. During
each session, blinded, placebo-controlled
chemical exposures were given, using iden-
tical procedures. Significantly more ofthe
chemically intolerant women (8/10, 80%)
exhibited increased sitting diastolic blood
pressure from week one to week two than
did the chemically tolerant women (4/17,
24%) (Fisher's Exact Test, p= 0.007).
Furthermore, the chemically intolerant
women who showed laboratory evidence of
blood pressure sensitization had lower
baseline prolactin levels, in contrast with
chemically tolerant women who did not
sensitize blood pressure (when a single
hyperprolactinemic outlier was removed)
(serum prolactin-CI: 7.8, SD 2.9; non-
CI: 11.9, SD 4.1, F(1,19) =6.1, p=0.024).
While these observations are preliminary,
the lower prolactin level suggests either:
increased baseline CNS dopamine activity
in the hypothalamus; or decreased CNS
hypothalamic dopamine with heightened
DA receptor sensitivity in the pituitary of
the chemically intolerant individuals. The
direction of the group difference for pro-
lactin levels is consistent with sensitization
ofdopaminergic activity to a low-level ini-
tiating stimulus (61), rather than sensitiza-
tion to a simple stress response model for
chemical intolerance (in which more stress
should lead to higher prolactin). However,
in view ofthe variability ofthe (-endorphin
data and one prolactin outlier, it will be
essential to replicate and extend the blood
studies to multiple measurements over dif-
ferent days and different times ofday, at
rest, and after chemical exposures, in larger
samples ofsubjects. Nonetheless, the data
overall suggest a labile but generally acti-
vated neurochemical internal milieu in
chemically intolerant individuals that may
involve atleastopioids anddopamine.
Design Implications of
Time-dependent Sensitization
Sensitizable andPreviously
SensiizedIndividuals
For present purposes, hypotheses that derive
from a TDS model have major design
implications for future studies ofexposure-
related symptoms in MCS (81). First, an
important hypothesis is that a subset of
MCS patients may be highly sensitizable
individuals, not only to environmental
chemicals, but also to foods, drugs, other
environmental factors, and life stressors
(2,21,27,81,88,98). This implies that envi-
ronmental chemicals may be the initiating
stimulus for the sensitizing process and
that chemicals may act synergistically with
other classes of stimuli to initiate MCS
(21,73). For example, it may be difficult
retrospectively to distinguish the sensitizing
physiological effects of an acute toxic
chemical spill of a single agent from the
sensitizing psychophysiological effects
of the associated stress response (e.g.,
,B-endorphin, cortisol) (99). It may still be
possible to try prospective pharmacological
agents (e.g., dopamine antagonists to block
certain types ofTDS initiation) (35,59) or
nonpharmacological interventions (e.g.,
briefcognitive psychotherapy to minimize
the perceived stressfulness of the event) at
the time ofemergency treatment in patients
exposed to a chemical spill, to determine
ifa given class of intervention might pre-
vent the later development ofMCS on a
TDS basis.
In the laboratory, cross-sensitization
between pharmacologic and nonpharmaco-
logic stimuli in TDS means that demon-
strating current reactivity to psychological
stressors such as placebo will not prove a
lack of reactivity to chemical stimuli, and
vice versa. The initial question then
becomes whether certain MCS patients are
sensitized to multiple environmental fac-
tors (98), rather than the dualistic question
ofa toxogenic versus psychogenic etiology
for MCS (100). It is also possible that dif-
ferent subsets of MCS patients experience
different types of initiation factors, i.e.,
some may have had early life psychological
or physical trauma without chemicals
(21,49) whereas others mayhave undergone
only an identifiable chemical exposure event
in mid-adulthood (12). Some chemical
exposure events such as a toxic spill could
invoke both stress and chemical effects to
initiate TDS, perhaps via the physiological
stress response pathways (72-75). Chemical
and stress responses may be dependent on
some ofthe same final common biological
mechanisms for initiation or elicitation of
sensitization (72,73). A key factor in TDS
may be the experienced or perceived threat
to the individual from the environment
(101,102). Studies must be designed to
manipulate systematically not only chemical
exposure levels and awareness ofchemicals,
but also the perceived stressfulness of the
setting in which the chemical exposures
occur (67,102).
Animal studies suggest that between-
group (different groups receiving the
active and sham treatments) rather than
within-group/crossover (the same groups
receiving the active and sham treatments
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in counterbalanced order) designs may
be optimal to differentiate the chemical
effects from those of experimental stress
(56,69,71,101,102). The difficulty for
within-subjects designs is that the sensitiz-
ing effects of either an active or a sham
exposure may change the subsequent
responsivity to the next test (sham or
active) in the same individual (56,61,64).
For example, Badiani et al. (67) found a
much less intense but nonetheless increased
response to saline injections in animals that
had been pretreated with active stimulant
drug in a novel environment, when sensi-
tizing and the test drug doses were all given
in a novel environment. However, the
saline effect was apparently conditioned to
specific circumstances. It was not present
for saline when the pretreatment had
involved active drug in a home environ-
ment, or saline in either home or novel
environment. These latter observations
may affect the interpretation of studies
such as those ofStaudenmayer et al. (103),
who reported an unreliable pattern of
MCS patient symptom data in differentiat-
ing chemical from sham challenges. The
within-subjects design and the pretesting of
masking odors to determine initial lack of
reactivity in that study may have initiated a
sensitization process to the testing proce-
dures or the masking odors in the MCS
patients. Consequently, subjects could have
been reactive in a seemingly unreliable
manner to various test exposures when
they were in fact sensitized to both active
and sham agents. This point is important
because of recent findings that mint odor,
for instance, used repeatedly as a masking
odor in Staudenmayer's human MCS
study (103), can initiate olfactory-limbic
sensitization in animals (34). Similarly,
examination of the study designs of
nonatopic adverse food reactions in MCS
patients suggests that a failure to appreciate
the implications ofsensitization can lead to
widely divergent experimental outcomes
(15,26). Systematic designs to test for sen-
sitization with awareness of its potential
interactions with contextual conditioning
and with adaptation are essential to avoid
methodological pitfalls in future MCS
chemical and sham exposure studies.
Context-dependent and
Context-independent
Sensitization
Second, as discussed above, TDS can
develop in either context-dependent (con-
ditioned) or context-independent ways
(35,55,59,67,102). That is, varying the
setting in which the sensitizing substance is
encountered will enable the individual to
exhibit a sensitized response in any setting
(context-independence). However, if the
chemical exposure is usually paired with
particular environmental, nonchemical
cues (context-dependence), then single ses-
sion studies in a novel laboratory situation
may miss a true effect. Studies have shown
that animals with established sensitization
who receive the test agent in a new cage
different from the one in which the drug
was usually given during initiation ofsensi-
tization will not show a sensitized response.
When returned to the original, drug-paired
setting, sensitized animals will again exhibit
heightened responsivity to the drug (35)
(Table 2). Furthermore, in established
context-dependent TDS, environmental
chemicals may not be the only eliciting
stimulus for symptoms. Some degree of
heightened response may occur in animals
given saline in the cage previously paired
with active drug (67). Consequently, the
inherent stressfulness, familiarity, or nov-
elty ofthe experimental setting and proce-
dures themselves may play a substantial
role in the outcome of MCS studies
involving TDS (35,67,69,71,75,104).
Both context-dependent and context-inde-
pendent sensitization theoretically might
occur in the same person. However, ani-
mals prone to drug self-administration
(71) may be particularly susceptible to the
context-dependent form; whereas animals
not prone to stimulant drug self-adminis-
tration (compare with a large subset of
MCS patients) (63) may be particularly
susceptible to the context-independent
form (71).
This argument implies that field studies
in familiar settings such as office, factory,
shopping malls, car, and home environ-
ments may be as important as laboratory
studies. In this manner, it may be possible
to detect sensitized responses to chemicals
that would be obscured in acute tests
within a novel and often threatening labo-
ratory setting. However, multiple test ses-
sions over periods ofdays and weeks in the
same setting would also help avoid type II
error by facilitating development and elici-
tation ofcontext-dependent sensitization to
the experimental procedures (67), even if
the ability to elicit pre-existing sensitization
were initially inhibited (35).
It is also possible to design studies to
differentiate conditioned from sensitized
response. For example, Stewart's group
(69) extinguished the conditioned compo-
nent ofa heightened response with saline
injections by repeated reexposure of
the animals to the previously drug-paired
environment until the size ofthe response
returned to baseline. However, when they
gave the drug again, the sensitized response
immediately reappeared, suggesting that
extinction addressed only the context-
dependent part ofthe process, not the sen-
sitization itself. Certain investigators have
claimed the ability to desensitize MCS
patients to chemicals by particular psycho-
logical extinction procedures (103). It
would be crucial to determine not only if
the procedures are actually effective in
some MCS patients, but also if such
extinction eliminates chemical sensitization
completely, or simply the conditioned elic-
itation ofadverse reactions in certain situa-
tions (69,71). The long-term health
implications of remaining sensitized, even
though not exhibiting context-dependent
sensitized reactions in some settings, are
unexamined at this time.
Sensitization and the
Adaptation Hypothesis
The sensitization hypothesis is compatible
with the MCS-derived adaptation hypothe-
sis; that is, a long-standing precept in MCS
is that the heightened reactivity and
another process, called masking or adapta-
tion, can develop at the same time (5,10).
The corollary hypothesis is that adaptation
may obscure the ability to detect sensitized
responses during challenge tests (Tables 1,
2). Complete removal from all adaptation-
inducing exposures for 4 or more days is
required prior to attempting definitive test-
ing for true adverse reactions to chemicals
(10). Simple environmental chambers are
insufficient, as subjects can remain in them
for only a few hours during a day, with lit-
tle impact on the adaptation process (5,10).
The practical and financial limitations of
developing environmentally controlled
units for research have impeded progress in
testing the adaptation hypothesis.
Historically, many neurobiological
researchers have noted that sensitization
and habituation (compare tolerance, adap-
tation) are distinct but interactive processes
(71,105,106). Post (106) pointed out that
continuous or frequent exposures to a given
stimulus favor development oftolerance,
whereas intermittent exposures favor devel-
opment of sensitization. Studies have
shown that sensitization and habituation
are not opposite ends ofthe same process,
but independent, concomitant processes
that can summate. Habituation added to an
otherwise sensitized response could result in
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mutual cancellation of effects, i.e., an
apparent lack ofchange over time (105).
Moreover, habituation to the test environ-
ment itself in an acute test ofa substance
can interact with individual differences in
inclination to drug self-administration to
alter drug response (35,67,71). Animal
studies indicate that MCS patients (who do
not tend to be drug abusers) might not
show their capacity for heightened reactiv-
ity to a chemical during an initial, one-ses-
sion test. Thus, the basic neuroscience
literature supports the MCS contention
that adaptation and cross-adaptation to
chronic chemical exposures could obscure
evidence ofheightened reactivity (Table 1).
Days, not hours, ofwithdrawal from the
sensitizing substance are needed to be able
to elicit a heightened response in TDS
(54,59,71). Individual differences in
responses to habituation to the total (chem-
ical, physical, and psychosocial) environ-
ment in which the substance is encountered
also may alter the outcome of a given
chemical challenge (35,71,102,107,108).
Time Factors in
Experimental Approaches
Available data indicate two primary ways
to design human studies testing for height-
ened reactivity to environmental chemicals:
a) place patients in an environmentally
controlled unit and remove them from all
sources ofthe suspect chemicals and cross-
sensitizing stimuli for a period of days
prior to challenge tests (10). This effec-
tively removes habituation while providing
optimal time for emergence of sensitiza-
tion; b) use inherently more versus less
sensitizable individuals and induce context-
dependent sensitization to common chemi-
cals in an initially novel laboratory setting
over multiple sessions, separated by days
from one another (2,68,98). Such a proce-
dure would make the heightened reactivity
to an otherwise familiar and habituated
substance dependent upon the new setting
in which it is encountered (67).
Design a relies largely on deadaptation
to reveal pre-existing, context-independent
sensitization. It is important to emphasize
that both sensitization and habituation
are likely to contribute to the reported
patterns ofreactivity in MCS patients in an
environmental control unit. (design a).
That is, ifadaptation to ambient exposures
outside the unit were the only issue, then
removing adaptation by avoidance for a
few days would restore not hyperreactiv-
ity, but simply reactivity. Instead, clini-
cians observed a marked hyperreactivity
(10,16), matching that of a sensitized
response (35,102).
Design b relies largely on experimen-
tally initiated, context-dependent (condi-
tioned) sensitization. The individual may
or may not have had preexisting sensitiza-
tion to the substance. The underlying
assumption is that the patient is inherently
more sensitizable than a normal person.
Design b takes advantage ofthe possibility
ofinducing and then testing for sensitiza-
tion by using the laboratory setting itselfto
make the first exposure to the substance
novel and the later exposures familiar, i.e.,
to foster context-dependent sensitization
(Table 2). Newlin and Thomson (68) have
already demonstrated the feasibility of
design b in human subjects. They com-
pared changes in autonomic nervous sys-
tem responses to ingestion ofalcohol on
three different days in sons of alcoholics
and sons of nonalcoholics (all ofwhom
used alcohol socially and nonabusively).
The outpatient sessions were spread over a
two-week period in the National Institute
of Drug Abuse laboratory. The sons of
alcoholics exhibited less ability to habituate
and more capacity to sensitize the auto-
nomic measures over sessions than did the
control subjects. They also tested for con-
ditioned responses to the laboratory setting
alone, without alcohol after the last session.
Autonomic patterns reverted to baseline
levels in the absence of alcohol. Thus, a
context-dependent sensitization to alcohol
was observed in sons of alcoholics, in
which the conditioned component relied
on concomitant exposure to the substance
and to the setting, not to the setting alone.
Our own preliminary polysomno-
graphic, quantitative EEG, endorphin,
and cardiovascular data suggest the feasi-
bility of the multiple, identical-session
design for MCS studies. This approach
may permit induction and elicitation of
sensitized responding in chemically intol-
erant human subjects without necessitat-
ing use of an environmentally controlled
hospital unit. However, designs a and b
facilitate asking different types of ques-
tions. For design a, the main question can
be whether the individual is currently
sensitive to a given substance. For design
b, the main question can be whether the
individual is unusually sensitizable.
Another important methodological
consideration is that exposure levels must
be intermittent and perhaps fluctuating,
with breaks ofhours and even days from
one exposure to the next, ifsensitization is
to develop (106). The constant levels of
chemicals used in many toxicology studies
could minimize sensitization and favor tol-
erance. Real-world exposures in human
populations are generally intermittent and
fluctuate over time. Previous investigators
have treated inconsistencies in dose during
laboratory studies as a potential procedural
flaw. On the contrary, the constancy and
lack ofinterruptions in experimental dos-
ing may help explain why tolerance has
been reported more often than sensitiza-
tion in toxicology research., The major
ethical consideration for this research in
humans is the need to limit the number of
repeated exposures during the research pro-
tocol. Kalivas et al. (59) point out that sen-
sitization to a few scattered exposures is
temporary and reversible, but massed daily
exposures for a week induce permanent
sensitization in animals.
Conclusions
MCS is much more than behavioral
avoidance of chemicals; explanations of
MCS must account for a broad range of
clinical observations (100). These obser-
vations include low rates of drug use and
abuse despite elevated levels of affective
distress (28). The partial limbic kindling
and TDS model has a limited, but grow-
ing, amount of empirical evidence in
humans (2,27,88,109) and in animals
(34,44,45,62,63) to support its involve-
ment in the multiple symptoms, phenom-
enology, and medical/psychiatric pictures
of MCS patients (81). In particular, the
sensitization model suggests specific
experimental design considerations, with-
out which one risks missing a true effect
(type II error). Previous hypotheses for
MCS involving sensitization, condition-
ing, and adaptation have often been con-
sidered in isolation from one another. To
design more appropriate chemical expo-
sure studies, it may be important to inte-
grate the various theoretical models and
empirical approaches to MCS with the
larger scientific literature on individual
differences in these potentially interactive
phenomena (35,59,67,69,71,105,106).
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